;PMID: 9248786
;source_file_1785.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..58] = [t:0..58]
;1)sentence:[e:64..139] = [t:64..139]
;2)section:[e:143..188] = [t:143..188]
;3)section:[e:192..283] = [t:192..283]
;4)sentence:[e:287..477] = [t:287..477]
;5)sentence:[e:478..711] = [t:478..711]
;6)sentence:[e:712..962] = [t:712..962]
;7)sentence:[e:963..1104] = [t:963..1104]
;8)sentence:[e:1105..1162] = [t:1105..1162]
;9)sentence:[e:1163..1325] = [t:1163..1325]
;10)sentence:[e:1326..1472] = [t:1326..1472]
;11)sentence:[e:1473..1586] = [t:1473..1586]
;12)sentence:[e:1588..1715] = [t:1588..1715]
;13)section:[e:1719..1763] = [t:1719..1763]

;section 0 Span:0..58
;Eur J Drug Metab Pharmacokinet. 1997 Apr-Jun;22(2):165-71.
(SEC
  (FRAG (NNP:[0..3] Eur) (NNP:[4..5] J) (NNP:[6..10] Drug) (NNP:[11..16] Metab)
        (NNP:[17..30] Pharmacokinet) (.:[30..31] .) (CD:[32..36] 1997)
        (NNP:[37..40] Apr) (::[40..41] -) (CD:[41..47] Jun;22)
        (-LRB-:[47..48] -LRB-) (CD:[48..49] 2) (-RRB-:[49..50] -RRB-)
        (CD:[50..54] :165) (::[54..55] -) (CD:[55..57] 71) (.:[57..58] .)))

;sentence 1 Span:64..139
;Interaction of chlormezanone with rat liver microsomes and its degradation.
;[79..92]:substance:"chlormezanone"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[64..75] Interaction))
      (PP (IN:[76..78] of)
        (NP (NN:[79..92] chlormezanone)))
      (PP (IN:[93..97] with)
        (NP (NN:[98..101] rat) (NN:[102..107] liver) (NNS:[108..118] microsomes))))
    (CC:[119..122] and)
    (NP (PRP$:[123..126] its) (NN:[127..138] degradation))
    (.:[138..139] .)))

;section 2 Span:143..188
;Klinger W, Oelschlager H, Karge E, Rothley D.
(SEC
  (FRAG (NNP:[143..150] Klinger) (NNP:[151..152] W) (,:[152..153] ,)
        (NNP:[154..165] Oelschlager) (NNP:[166..168] H,) (NNP:[169..174] Karge)
        (NNP:[175..176] E) (,:[176..177] ,) (NNP:[178..185] Rothley)
        (NNP:[186..188] D.)))

;section 3 Span:192..283
;Institut fur Pharmakologie und Toxikologie, Friedrich-Schiller-Universitat, 
;Jena, Germany.
(SEC
  (FRAG (NNP:[192..200] Institut) (NN:[201..204] fur)
        (NNP:[205..218] Pharmakologie) (VBD:[219..222] und)
        (NNP:[223..234] Toxikologie) (,:[234..235] ,)
        (NNP:[236..254] Friedrich-Schiller) (NNP:[254..266] -Universitat)
        (,:[266..267] ,) (NNP:[269..273] Jena) (,:[273..274] ,)
        (NNP:[275..282] Germany) (.:[282..283] .)))

;sentence 4 Span:287..477
;Chlormezanone binds to oxidized cytochrome P450 in rat liver microsomes with
;a  binding curve according to type I like hexobarbital but less pronounced
;and with  a general shift to the left.
;[287..300]:substance:"Chlormezanone"
;[319..334]:cyp450:"cytochrome P450"
;[406..418]:substance:"hexobarbital"
(SENT
  (S
    (NP-SBJ (NN:[287..300] Chlormezanone))
    (VP (VBZ:[301..306] binds)
      (PP-CLR (TO:[307..309] to)
        (NP (VBN:[310..318] oxidized)
           (NN:[319..329] cytochrome) (NN:[330..334] P450)))
      (PP-LOC (IN:[335..337] in)
        (NP (NN:[338..341] rat) (NN:[342..347] liver)
            (NNS:[348..358] microsomes)))
      (PP (IN:[359..363] with)
        (NP
          (NP (DT:[364..365] a) (VBG:[367..374] binding) (NN:[375..380] curve))
          (VP (VBG:[381..390] according)
            (PP (TO:[391..393] to)
              (NP (NN:[394..398] type) (CD:[399..400] I))))
          (UCP
            (PP (IN:[401..405] like)
              (NP (NN:[406..418] hexobarbital)))
            (CC:[419..422] but)
            (UCP
              (ADJP (RBR:[423..427] less) (JJ:[428..438] pronounced))
              (CC:[439..442] and)
              (PP (IN:[443..447] with)
                (NP
                  (NP (DT:[449..450] a) (JJ:[451..458] general)
                      (NN:[459..464] shift))
                  (PP (TO:[465..467] to)
                    (NP (DT:[468..471] the) (NN:[472..476] left))))))))))
    (.:[476..477] .)))

;sentence 5 Span:478..711
;Ethylmorphine N-demethylation, ethoxycoumarin and  ethoxyresorufin
;O-deethylation are inhibited by chlormezanone in mM  concentrations only
;whereas pentoxyresorufin O-depentylation is inhibited by  about 50% in microM
;concentrations.
;[478..491]:substance:"Ethylmorphine"
;[509..523]:substance:"ethoxycoumarin"
;[529..544]:substance:"ethoxyresorufin"
;[577..590]:substance:"chlormezanone"
;[594..596]:quantitative-units:"mM"
;[626..642]:substance:"pentoxyresorufin"
;[682..685]:quantitative-value:"50%"
;[689..695]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[478..491] Ethylmorphine) (NN:[492..507] N-demethylation))
      (,:[507..508] ,)
      (NP (NN:[509..523] ethoxycoumarin)
        (NML-3 (-NONE-:[523..523] *P*)))
      (CC:[524..527] and)
      (NP (NN:[529..544] ethoxyresorufin)
        (NML-3 (NN:[545..559] O-deethylation))))
    (VP (VBP:[560..563] are)
      (VP (VBN:[564..573] inhibited)
        (NP-2 (-NONE-:[573..573] *))
        (PP (IN:[574..576] by)
          (NP-LGS (NN:[577..590] chlormezanone)))
        (PP (IN:[591..593] in)
          (NP (NN:[594..596] mM) (NNS:[598..612] concentrations)))
        (ADVP (RB:[613..617] only))))
    (SBAR-ADV (IN:[618..625] whereas)
      (S
        (NP-SBJ-1 (NN:[626..642] pentoxyresorufin)
                  (NN:[643..658] O-depentylation))
        (VP (VBZ:[659..661] is)
          (VP (VBN:[662..671] inhibited)
            (NP-1 (-NONE-:[671..671] *))
            (PP (IN:[672..674] by)
              (NP-EXT
                (QP (RB:[676..681] about) (CD:[682..684] 50))
                (NN:[684..685] %)))
            (PP (IN:[686..688] in)
              (NP (NN:[689..695] microM) (NNS:[696..710] concentrations)))))))
    (.:[710..711] .)))

;sentence 6 Span:712..962
;Luminol and lucigenin amplified  chemiluminescence indicating the formation
;of reactive oxygen species was not  influenced in concentration ranges
;between mM and microM, whereas NADPH/Fe  stimulated lipid peroxidation showed
;a tendency of inhibition.
;[712..719]:substance:"Luminol"
;[724..733]:substance:"lucigenin"
;[800..814]:substance:"oxygen species"
;[867..869]:quantitative-units:"mM"
;[874..880]:quantitative-units:"microM"
;[890..895]:substance:"NADPH"
;[896..898]:substance:"Fe"
;[911..916]:substance:"lipid"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (ADJP
          (NML (NN:[712..719] Luminol) (CC:[720..723] and)
               (NN:[724..733] lucigenin))
          (VBD:[734..743] amplified))
        (NN:[745..762] chemiluminescence))
      (VP (VBG:[763..773] indicating)
        (NP
          (NP (DT:[774..777] the) (NN:[778..787] formation))
          (PP (IN:[788..790] of)
            (NP (JJ:[791..799] reactive)
               (NN:[800..806] oxygen) (NN:[807..814] species))))))
    (VP (VBD:[815..818] was) (RB:[819..822] not)
      (VP (VBN:[824..834] influenced)
        (NP-1 (-NONE-:[834..834] *))
        (PP (IN:[835..837] in)
          (NP
            (NP (NN:[838..851] concentration) (NNS:[852..858] ranges))
            (PP (IN:[859..866] between)
              (NP (NN:[867..869] mM) (CC:[870..873] and) (NN:[874..880] microM)))))))
    (,:[880..881] ,)
    (SBAR-ADV (IN:[882..889] whereas)
      (S
        (NP-SBJ
          (ADJP
            (NML (NN:[890..895] NADPH) (SYM:[895..896] /) (NN:[896..898] Fe))
            (VBN:[900..910] stimulated))
          (NN:[911..916] lipid) (NN:[917..929] peroxidation))
        (VP (VBD:[930..936] showed)
          (NP
            (NP (DT:[937..938] a) (NN:[939..947] tendency))
            (PP (IN:[948..950] of)
              (NP (NN:[951..961] inhibition)))))))
    (.:[961..962] .)))

;sentence 7 Span:963..1104
;But scavenger  activity could not be demonstrated: the zymosan stimulated
;chemiluminescence of  whole blood was not influenced significantly.
;[1018..1025]:substance:"zymosan"
(SENT
  (S
    (S
      (ADVP (CC:[963..966] But))
      (NP-SBJ-2 (NN:[967..976] scavenger) (NN:[978..986] activity))
      (VP (MD:[987..992] could) (RB:[993..996] not)
        (VP (VB:[997..999] be)
          (VP (VBN:[1000..1012] demonstrated)
            (NP-2 (-NONE-:[1012..1012] *))))))
    (::[1012..1013] :)
    (S
      (NP-SBJ-1
        (NP (DT:[1014..1017] the)
          (ADJP (NN:[1018..1025] zymosan) (VBN:[1026..1036] stimulated))
          (NN:[1037..1054] chemiluminescence))
        (PP (IN:[1055..1057] of)
          (NP (JJ:[1059..1064] whole) (NN:[1065..1070] blood))))
      (VP (VBD:[1071..1074] was) (RB:[1075..1078] not)
        (VP (VBN:[1079..1089] influenced)
          (NP-1 (-NONE-:[1089..1089] *))
          (ADVP-MNR (RB:[1090..1103] significantly)))))
    (.:[1103..1104] .)))

;sentence 8 Span:1105..1162
;The degradation process of  chlormezanone was elucidated.
;[1133..1146]:substance:"chlormezanone"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1105..1108] The) (NN:[1109..1120] degradation)
          (NN:[1121..1128] process))
      (PP (IN:[1129..1131] of)
        (NP (NN:[1133..1146] chlormezanone))))
    (VP (VBD:[1147..1150] was)
      (VP (VBN:[1151..1161] elucidated)
        (NP-1 (-NONE-:[1161..1161] *))))
    (.:[1161..1162] .)))

;sentence 9 Span:1163..1325
;The first step involves ring opening by chemical  hydrolysis with subsequent
;formation of an unstable acylhalfaminal which is the  source of
;4-chlorobenzaldehyde.
;[1203..1211]:substance:"chemical"
;[1265..1279]:substance:"acylhalfaminal"
;[1304..1324]:substance:"4-chlorobenzaldehyde"
(SENT
  (S
    (NP-SBJ (DT:[1163..1166] The) (JJ:[1167..1172] first) (NN:[1173..1177] step))
    (VP (VBZ:[1178..1186] involves)
      (NP
        (NP (NN:[1187..1191] ring) (NN:[1192..1199] opening))
        (PP (IN:[1200..1202] by)
          (NP (JJ:[1203..1211] chemical) (NN:[1213..1223] hydrolysis)))
        (PP (IN:[1224..1228] with)
          (NP
            (NP (JJ:[1229..1239] subsequent) (NN:[1240..1249] formation))
            (PP (IN:[1250..1252] of)
              (NP
                (NP (DT:[1253..1255] an) (JJ:[1256..1264] unstable)
                    (NN:[1265..1279] acylhalfaminal))
                (SBAR
                  (WHNP-1 (WDT:[1280..1285] which))
                  (S
                    (NP-SBJ-1 (-NONE-:[1285..1285] *T*))
                    (VP (VBZ:[1286..1288] is)
                      (NP-PRD
                        (NP (DT:[1289..1292] the) (NN:[1294..1300] source))
                        (PP (IN:[1301..1303] of)
                          (NP (NN:[1304..1324] 4-chlorobenzaldehyde)))))))))))))
    (.:[1324..1325] .)))

;sentence 10 Span:1326..1472
;This aldehyde undergoes enzymatically controlled  oxidation to
;4-chlorobenzoic acid which is the parent compound of following  phase II
;reactions.
;[1331..1339]:substance:"aldehyde"
;[1389..1409]:substance:"4-chlorobenzoic acid"
;[1430..1438]:substance:"compound"
(SENT
  (S
    (NP-SBJ (DT:[1326..1330] This) (NN:[1331..1339] aldehyde))
    (VP (VBZ:[1340..1349] undergoes)
      (NP
        (NP
          (ADJP (RB:[1350..1363] enzymatically) (VBN:[1364..1374] controlled))
          (NN:[1376..1385] oxidation))
        (PP (TO:[1386..1388] to)
          (NP
            (NP (JJ:[1389..1404] 4-chlorobenzoic) (NN:[1405..1409] acid))
            (SBAR
              (WHNP-1 (WDT:[1410..1415] which))
              (S
                (NP-SBJ-1 (-NONE-:[1415..1415] *T*))
                (VP (VBZ:[1416..1418] is)
                  (NP-PRD
                    (NP (DT:[1419..1422] the) (NN:[1423..1429] parent)
                        (NN:[1430..1438] compound))
                    (PP (IN:[1439..1441] of)
                      (NP (VBG:[1442..1451] following)
                        (NML (NN:[1453..1458] phase) (CD:[1459..1461] II))
                        (NNS:[1462..1471] reactions)))))))))))
    (.:[1471..1472] .)))

;sentence 11 Span:1473..1586
;The second degradation product is 
;2-carboxyethane-sulfinic-acid-N-methylamide, which is hydrolyzed very
;quickly.
;[1496..1503]:substance:"product"
;[1508..1551]:substance:"2-carboxyethane-sulfinic-acid-N-methylamide"
(SENT
  (S
    (NP-SBJ (DT:[1473..1476] The) (JJ:[1477..1483] second)
            (NN:[1484..1495] degradation) (NN:[1496..1503] product))
    (VP (VBZ:[1504..1506] is)
      (NP-PRD
        (NP (NN:[1508..1551] 2-carboxyethane-sulfinic-acid-N-methylamide))
        (,:[1551..1552] ,)
        (SBAR
          (WHNP-1 (WDT:[1553..1558] which))
          (S
            (NP-SBJ-1 (-NONE-:[1558..1558] *T*))
            (VP (VBZ:[1559..1561] is)
              (VP (VBN:[1562..1572] hydrolyzed)
                (NP-1 (-NONE-:[1572..1572] *))
                (ADVP-MNR (RB:[1573..1577] very) (RB:[1578..1585] quickly))))))))
    (.:[1585..1586] .)))

;sentence 12 Span:1588..1715
;Neither oxidation of the sulfinic acid or its N-methylamide derivative could
;be  observed nor N-demethylation of chlormezanone.
;[1613..1626]:substance:"sulfinic acid"
;[1634..1658]:substance:"N-methylamide derivative"
;[1701..1714]:substance:"chlormezanone"
(SENT
  (S (CC:[1588..1595] Neither)
    (S
      (NP-SBJ-1
        (NP (NN:[1596..1605] oxidation))
        (PP (IN:[1606..1608] of)
          (NP
            (NP (DT:[1609..1612] the)
               (JJ:[1613..1621] sulfinic) (NN:[1622..1626] acid))
            (CC:[1627..1629] or)
            (NP (PRP$:[1630..1633] its)
               (NN:[1634..1647] N-methylamide) (NN:[1648..1658] derivative)))))
      (VP (MD:[1659..1664] could)
        (VP (VB:[1665..1667] be)
          (VP (VBN:[1669..1677] observed)
            (NP-1 (-NONE-:[1677..1677] *))))))
    (CC:[1678..1681] nor)
    (S
      (NP-SBJ
        (NP (NN:[1682..1697] N-demethylation))
        (PP (IN:[1698..1700] of)
          (NP (NN:[1701..1714] chlormezanone))))
      (VP (-NONE-:[1714..1714] *?*)))
    (.:[1714..1715] .)))

;section 13 Span:1719..1763
;PMID: 9248786 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1719..1723] PMID) (::[1723..1724] :) (CD:[1725..1732] 9248786)
        (NN:[1733..1734] -LSB-) (NNP:[1734..1740] PubMed) (::[1741..1742] -)
        (NN:[1743..1750] indexed) (IN:[1751..1754] for)
        (NNP:[1755..1763] MEDLINE-RSB-)))
